Is CLRB or BTMD more profitable?

biote has a net margin of 8.29% compared to Cellectar Biosciences' net margin of 0.00%. biote's return on equity of -25.72% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% biote 8.29% -25.72% 15.12%

Does the media refer more to CLRB or BTMD?

In the previous week, Cellectar Biosciences had 5 more articles in the media than biote. MarketBeat recorded 9 mentions for Cellectar Biosciences and 4 mentions for biote. biote's average media sentiment score of 1.37 beat Cellectar Biosciences' score of 1.22 indicating that biote is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive biote 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, CLRB or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A

Is CLRB or TELO more profitable?

Telomir Pharmaceuticals' return on equity of -201.23% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% Telomir Pharmaceuticals N/A -201.23% -172.71%

Does the media refer more to CLRB or TELO?

In the previous week, Cellectar Biosciences had 7 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 9 mentions for Cellectar Biosciences and 2 mentions for Telomir Pharmaceuticals. Cellectar Biosciences' average media sentiment score of 1.22 beat Telomir Pharmaceuticals' score of 0.94 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FRMM or CLRB more profitable?

Forum Markets' return on equity of -242.09% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% Cellectar Biosciences N/A -349.24% -153.18%

Does the media favor FRMM or CLRB?

In the previous week, Forum Markets had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 11 mentions for Forum Markets and 9 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 1.22 beat Forum Markets' score of 0.62 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forum Markets 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CLRB or RLYB?

In the previous week, Cellectar Biosciences had 6 more articles in the media than Rallybio. MarketBeat recorded 9 mentions for Cellectar Biosciences and 3 mentions for Rallybio. Cellectar Biosciences' average media sentiment score of 1.22 beat Rallybio's score of 0.88 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rallybio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, LONA or CLRB?

Athira Pharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$5.21 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is LONA or CLRB more profitable?

Cellectar Biosciences' return on equity of -349.24% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -381.01% -225.74% Cellectar Biosciences N/A -349.24% -153.18%

Does the media refer more to LONA or CLRB?

In the previous week, Cellectar Biosciences had 6 more articles in the media than Athira Pharma. MarketBeat recorded 9 mentions for Cellectar Biosciences and 3 mentions for Athira Pharma. Cellectar Biosciences' average media sentiment score of 1.22 beat Athira Pharma's score of 0.62 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cellectar Biosciences (CLRB) Competitors

$2.63 0.00 (0.00%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$2.59 -0.04 (-1.52%)

As of 06:08 AM Eastern

Compare

CLRB vs. BTMD, TELO, FRMM, RLYB, and LONA

Should you buy Cellectar Biosciences stock or one of its competitors? MarketBeat compares Cellectar Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellectar Biosciences include biote (BTMD), Telomir Pharmaceuticals (TELO), Forum Markets (FRMM), Rallybio (RLYB), and Athira Pharma (LONA). These companies are all part of the "pharmaceutical products" industry.

How does Cellectar Biosciences compare to biote?

Cellectar Biosciences (NASDAQ:CLRB) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Cellectar Biosciences presently has a consensus target price of $11.00, suggesting a potential upside of 318.25%. biote has a consensus target price of $2.75, suggesting a potential upside of 25.57%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Cellectar Biosciences is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

biote has a net margin of 8.29% compared to Cellectar Biosciences' net margin of 0.00%. biote's return on equity of -25.72% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
biote	8.29%	-25.72%	15.12%

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 32.4% of biote shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

biote has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
biote	$192.22M	0.43	$27.05M	$0.44	4.98

Cellectar Biosciences has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, biote has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

In the previous week, Cellectar Biosciences had 5 more articles in the media than biote. MarketBeat recorded 9 mentions for Cellectar Biosciences and 4 mentions for biote. biote's average media sentiment score of 1.37 beat Cellectar Biosciences' score of 1.22 indicating that biote is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
biote	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

biote beats Cellectar Biosciences on 11 of the 15 factors compared between the two stocks.

How does Cellectar Biosciences compare to Telomir Pharmaceuticals?

Cellectar Biosciences (NASDAQ:CLRB) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Cellectar Biosciences presently has a consensus target price of $11.00, indicating a potential upside of 318.25%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cellectar Biosciences is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cellectar Biosciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Telomir Pharmaceuticals' return on equity of -201.23% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

16.4% of Cellectar Biosciences shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Cellectar Biosciences had 7 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 9 mentions for Cellectar Biosciences and 2 mentions for Telomir Pharmaceuticals. Cellectar Biosciences' average media sentiment score of 1.22 beat Telomir Pharmaceuticals' score of 0.94 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cellectar Biosciences beats Telomir Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Cellectar Biosciences compare to Forum Markets?

Forum Markets (NASDAQ:FRMM) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Forum Markets has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

In the previous week, Forum Markets had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 11 mentions for Forum Markets and 9 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 1.22 beat Forum Markets' score of 0.62 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectar Biosciences has lower revenue, but higher earnings than Forum Markets. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$9.41M	9.68	-$450.52M	-$36.07	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

Forum Markets' return on equity of -242.09% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Forum Markets currently has a consensus price target of $10.00, indicating a potential upside of 47.06%. Cellectar Biosciences has a consensus price target of $11.00, indicating a potential upside of 318.25%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

4.1% of Forum Markets shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 25.2% of Forum Markets shares are held by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Forum Markets and Cellectar Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Cellectar Biosciences compare to Rallybio?

Cellectar Biosciences (NASDAQ:CLRB) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

In the previous week, Cellectar Biosciences had 6 more articles in the media than Rallybio. MarketBeat recorded 9 mentions for Cellectar Biosciences and 3 mentions for Rallybio. Cellectar Biosciences' average media sentiment score of 1.22 beat Rallybio's score of 0.88 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rallybio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectar Biosciences currently has a consensus price target of $11.00, suggesting a potential upside of 318.25%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cellectar Biosciences is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cellectar Biosciences has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Rallybio	-911.07%	-55.79%	-51.48%

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by company insiders. Comparatively, 10.3% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cellectar Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market.

Rallybio has higher revenue and earnings than Cellectar Biosciences. Rallybio is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Rallybio	$860K	98.67	-$8.98M	-$4.34	N/A

Summary

Cellectar Biosciences beats Rallybio on 9 of the 16 factors compared between the two stocks.

How does Cellectar Biosciences compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Athira Pharma presently has a consensus target price of $15.00, suggesting a potential upside of 58.98%. Cellectar Biosciences has a consensus target price of $11.00, suggesting a potential upside of 318.25%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Cellectar Biosciences had 6 more articles in the media than Athira Pharma. MarketBeat recorded 9 mentions for Cellectar Biosciences and 3 mentions for Athira Pharma. Cellectar Biosciences' average media sentiment score of 1.22 beat Athira Pharma's score of 0.62 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectar Biosciences' return on equity of -349.24% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Cellectar Biosciences	N/A	-349.24%	-153.18%

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 25.7% of Athira Pharma shares are held by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Athira Pharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

Athira Pharma has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Summary

Cellectar Biosciences beats Athira Pharma on 9 of the 13 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLRB vs. The Competition

Export

Metric	Cellectar Biosciences	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.02M	$8.67B	$6.86B	$12.44B
Dividend Yield	N/A	2.55%	2.68%	8.42%
P/E Ratio	-0.39	15.65	27.01	24.38
Price / Sales	N/A	6.52	521.33	91.92
Price / Cash	N/A	18.09	48.59	59.36
Price / Book	1.39	3.56	10.95	6.33
Net Income	-$21.79M	$228.19M	$3.59B	$331.02M
7 Day Performance	-2.23%	-1.41%	-1.45%	-0.33%
1 Month Performance	12.39%	-2.08%	2.78%	-1.29%
1 Year Performance	-44.98%	2.26%	28.53%	21.30%

Cellectar Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLRB Cellectar Biosciences	4.2617 of 5 stars	$2.63 flat	$11.00 +318.3%	-47.2%	$21.02M	N/A	N/A	10	News Coverage Positive News Analyst Upgrade Short Interest Increase Analyst Revision
BTMD biote	4.6796 of 5 stars	$2.29 +0.6%	$2.75 +19.9%	-45.8%	$85.57M	$188.16M	5.18	194	News Coverage Positive News Short Interest Decrease
TELO Telomir Pharmaceuticals	0.5674 of 5 stars	$1.24 -2.4%	N/A	+6.0%	$84.94M	N/A	N/A	1
FRMM Forum Markets	3.3331 of 5 stars	$5.85 -14.1%	$10.00 +70.9%	N/A	$84.91M	$6.55M	N/A	7	News Coverage Analyst Revision
RLYB Rallybio	0.8707 of 5 stars	$15.65 -0.4%	N/A	+376.5%	$82.95M	$860K	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLRB) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectar Biosciences (CLRB) Competitors

CLRB vs. BTMD, TELO, FRMM, RLYB, and LONA

How does Cellectar Biosciences compare to biote?

Summary

How does Cellectar Biosciences compare to Telomir Pharmaceuticals?

Summary

How does Cellectar Biosciences compare to Forum Markets?

Summary

How does Cellectar Biosciences compare to Rallybio?

Summary

How does Cellectar Biosciences compare to Athira Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectar Biosciences (CLRB) Competitors

CLRB vs. BTMD, TELO, FRMM, RLYB, and LONA

How does Cellectar Biosciences compare to biote?

Do analysts rate CLRB or BTMD?

Is CLRB or BTMD more profitable?

Do insiders and institutionals hold more shares of CLRB or BTMD?

Which has better earnings & valuation, CLRB or BTMD?

Which has more risk & volatility, CLRB or BTMD?

Does the media refer more to CLRB or BTMD?

Summary

How does Cellectar Biosciences compare to Telomir Pharmaceuticals?

Which has preferable earnings & valuation, CLRB or TELO?

Do analysts recommend CLRB or TELO?

Which has more risk and volatility, CLRB or TELO?

Is CLRB or TELO more profitable?

Do institutionals and insiders believe in CLRB or TELO?

Does the media refer more to CLRB or TELO?

Summary

How does Cellectar Biosciences compare to Forum Markets?

Which has more risk & volatility, FRMM or CLRB?

Does the media favor FRMM or CLRB?

Which has stronger earnings & valuation, FRMM or CLRB?

Is FRMM or CLRB more profitable?

Do analysts recommend FRMM or CLRB?

Do insiders and institutionals believe in FRMM or CLRB?

Summary

How does Cellectar Biosciences compare to Rallybio?

Does the media prefer CLRB or RLYB?

Do analysts recommend CLRB or RLYB?

Is CLRB or RLYB more profitable?

Do institutionals and insiders have more ownership in CLRB or RLYB?

Which has more risk & volatility, CLRB or RLYB?

Which has preferable valuation and earnings, CLRB or RLYB?

Summary

How does Cellectar Biosciences compare to Athira Pharma?

Do analysts recommend LONA or CLRB?

Does the media refer more to LONA or CLRB?

Is LONA or CLRB more profitable?

Do insiders & institutionals have more ownership in LONA or CLRB?

Which has preferable valuation & earnings, LONA or CLRB?

Which has more volatility & risk, LONA or CLRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools